Protocol Ledger

NCT06290505 · Phase II · RECRUITING

A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study

Interventional Phase II clinical trial protocol NCT06290505 sponsored by Australasian Gastro-Intestinal Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-08 Enrollment: 54 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06290505
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)54 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06290505
Protocol FieldVerified Registry Value
NCT IdentifierNCT06290505
Consolidated Lead SponsorAustralasian Gastro-Intestinal Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment54 participants (ESTIMATED)
Registered Start Date2021-12-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06290505
Hospital Research SiteLocationSite Profile
Royal Brisbane and Women's HospitalHerston, AustraliaOpen Hospital Dossier ->
Flinders Medical CentreBedford Park, AustraliaOpen Hospital Dossier ->
Peter MacCallum Cancer CentreMelbourne, AustraliaOpen Hospital Dossier ->
Sir Charles Gairdner HospitalNedlands, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI